Physician profile
Eric Jie Yang
NPI 1659831204
$4,562.40
in general payments reported to CMS, 2019-2025
17 companies · $187 in 2025
The $187 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $104 · 2021: $429 · 2022: $1,617 · 2023: $1,990 · 2024: $235 · 2025: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,238 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,237.65 |
| Education | $174.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $664.80 | 2021-2023 | |
| Janssen Scientific Affairs, LLC | $604.62 | 2021-2023 | |
| Ucb, INC. | $591.52 | 2022-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $551.30 | 2021-2023 | Tremfya, Stelara |
| E.R. Squibb & Sons, L.L.C. | $373.29 | 2022-2025 | Sotyktu, Reblozyl |
| Novartis Pharmaceuticals Corporation | $315.61 | 2022-2023 | |
| Galderma Laboratories, L.P. | $293.76 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $249.95 | 2022-2023 | |
| Incyte Corporation | $206.51 | 2023 | Opzelura |
| Abbvie INC. | $205.36 | 2023 | Natrelle Saline-Filled Breast Implants, Revolve, Botox |
| Amgen INC. | $106.98 | 2023 | Otezla |
| Dermavant Sciences, INC. | $106.83 | 2023 | Vtama |
| Convatec INC. | $103.81 | 2020 | |
| Pfizer INC. | $99.98 | 2024 | |
| Celgene Corporation | $47.90 | 2025 | Reblozyl |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $20.73 | 2023 | Taltz, Olumiant |
| Pierre Fabre Pharmaceuticals, INC. | $19.45 | 2023 | Hemangeol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.